cisplatin/gemcitabine

Known as: gemcitabine cisplatin, cisplatin gemcitabine, CDDP/dFdC 
A chemotherapy combination used to treat malignant mesothelioma, advanced non-small cell lung cancer, advanced bladder cancer, advanced cervical… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1997-2017
0102019972017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2012
Highly Cited
2012
PURPOSE The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
PURPOSE This trial evaluated the efficacy and safety of sorafenib plus gemcitabine/cisplatin in chemotherapy-naive patients with… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
PURPOSE To determine whether addition of gemcitabine to concurrent cisplatin chemoradiotherapy and as adjuvant chemotherapy with… (More)
Is this relevant?
Highly Cited
2009
Highly Cited
2009
PURPOSE Bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor, improves survival when combined with… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Cisplatin plus gemcitabine is a standard regimen for first-line treatment of advanced non-small-cell lung cancer (NSCLC… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2008
Highly Cited
2008
PURPOSE Selecting patients according to key genetic characteristics may help to tailor chemotherapy and optimize the treatment in… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
2007
Highly Cited
2007
BACKGROUND Customizing chemotherapy on the basis of chemosentitivity prediction may improve outcome in advanced bladder cancer… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND Pivotal studies indicate a role of excision repair cross-complementation 1 (ERCC1) gene and ribonucleotide reductase… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
BACKGROUND Impaired DNA repair capacity may favorably affect survival in cisplatin/gemcitabine-treated non-small-cell lung cancer… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE No chemotherapy regimen, including the widely used combination of gemcitabine/cisplatin, confers significantly improved… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?